Amy Lin, MD
Professor
Medicine
School of Medicine

From 2005 to 2018, Dr. Lin worked in a multidisciplinary team of medical oncologists, radiation oncologists, and urologic surgical oncologists both at UCSF and the San Francisco Veterans Administration Medical Center providing specialized outpatient patient care to all types of genitourinary malignancies including prostate, kidney, bladder and testicular cancer. In 2018, Dr. Lin joined UCSF’s inpatient hospital-based solid tumor oncology program as a faculty member and chief of clinical operations. She also serves as the Medical Director of Clinical Informatics and Data Analytics for Adult Cancer Services at the Helen Diller Comprehensive Cancer Center. She is currently a Professor of Medicine and Urology.

Dr. Lin’s focus is on improving clinical care workflows to optimize health care delivery. She is interested in how health care technology can enhance certain aspects of patient care and believes that increasing the quality of health care data collection, integration of multi-source patient health care data, and data interoperability are key to these efforts. Dr. Lin has been an active subject matter expert on electronic health record (EHR) clinical workflows within the Cancer Center.

• Factors Associated With Participation in the Chronic Disease Self-Management Program: Findings From the SUCCEED Trial.
  Stroke 2020 Lin AM, Vickrey BG, Barry F, Lee ML, Ayala-Rivera M, Cheng E, Montoya AV, Mojarro-Huang E, Gomez P, Castro M, Corrales M, Sivers-Teixeira T, Tran JL, Johnson R, Ediss C, Shaby B, Willis P, Sanossian N…
• Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness.
  The American journal of psychiatry 2020 Ching CRK, Gutman BA, Sun D, Villalon Reina J, Ragothaman A, Isaev D, Zavaliangos-Petropulu A, Lin A, Jonas RK, Kushan L, Pacheco-Hansen L, Vajdi A, Forsyth JK, Jalbrzikowski M, Bakker G, van …
• Less Than Ideal: Trends in Cardiovascular Health Among US Stroke Survivors.
  Stroke 2018 Lin AM, Lin MP, Markovic D, Ovbiagele B, Sanossian N, Towfighi A
• Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
  Clinical genitourinary cancer 2018 Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R
• A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
  The oncologist 2018 Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ
• High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
  Clinical genitourinary cancer 2017 Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R…
• A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.
  The oncologist 2017 Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ
• A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
  Urologic oncology 2017 Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ
• Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.
  Cancer immunology research 2016 Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L
• Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.
  Cancer immunology research 2015 Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L
• Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
  Clinical genitourinary cancer 2014 Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ
• Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ
• Intestinal tumor suppression in ApcMin/+ mice by prostaglandin D2 receptor PTGDR.
  Cancer medicine 2014 Tippin BL, Kwong AM, Inadomi MJ, Lee OJ, Park JM, Materi AM, Buslon VS, Lin AM, Kudo LC, Karsten SL, French SW, Narumiya S, Urade Y, Salido E, Lin HJ
• Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Hickey MJ, Malone CC, Erickson KL, Lin A, Soto H, Ha ET, Kamijima S, Inagaki A, Takahashi M, Kato Y, Kasahara N, Mueller BM, Kruse CA
• A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.
  Oncology reports 2011 Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ
• Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer.
  Prostaglandins & other lipid mediators 2011 Tippin BL, Levine AJ, Materi AM, Song WL, Keku TO, Goodman JE, Sansbury LB, Das S, Dai A, Kwong AM, Lin AM, Lin JM, Park JM, Patterson RE, Chlebowski RT, Garavito RM, Inoue T, Cho W, Lawson JA, Kapoor…
• A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
  Cancer 2011 Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE
• Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences.
  Journal of computer assisted tomography 2011 Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV
• Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
  Urologic oncology 2010 Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ
• Asymptomatic maternal combined homocystinuria and methylmalonic aciduria (cblC) detected through low carnitine levels on newborn screening.
  The Journal of pediatrics 2009 Lin HJ, Neidich JA, Salazar D, Thomas-Johnson E, Ferreira BF, Kwong AM, Lin AM, Jonas AJ, Levine S, Lorey F, Rosenblatt DS
• Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
  Cancer research 2009 Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ
• Prostate cancer update: 2007.
  Current opinion in oncology 2008 Lin AM, Small EJ
• A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
  BJU international 2008 Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF
• Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
  The Journal of urology 2007 Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ
• Management of hormone refractory prostate cancer.
  Current opinion in supportive and palliative care 2007 Lin AM, Small EJ
• A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
  Clinical genitourinary cancer 2007 Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ
• Prostate cancer update: 2006.
  Current opinion in oncology 2007 Lin AM, Small EJ
• The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
  Current treatment options in oncology 2007 Lin A, Rugo HS
• Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
  Critical reviews in oncology/hematology 2006 Lin AM, Ryan CJ, Small EJ
• A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
  BJU international 2006 Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ
• Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
  Urologic oncology 2006 Lin AM, Hershberg RM, Small EJ
• Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
  Urologic oncology 2006 Ryan CJ, Lin AM, Small EJ
• Clinical trials in patients with biochemically relapsed prostate cancer.
  BJU international 2006 Lin AM, Rini BI, Small EJ